Stevanato Group S.p.A. (STVN): Price and Financial Metrics Recent IPO
GET POWR RATINGS... FREE!
STVN Stock Price Chart Interactive Chart >
STVN Price/Volume Stats
|Current price||$26.92||52-week high||$28.66|
|Prev. close||$26.89||52-week low||$16.61|
|Day high||$27.80||Avg. volume||855,167|
|50-day MA||$0.00||Dividend yield||N/A|
|200-day MA||$0.00||Market Cap||7.94B|
Stevanato Group S.p.A. (STVN) Company Bio
Stevanato Group S.p.A. engages in the design, production, and distribution of products and systems to provide integrated solutions for pharma and healthcare. Its principal products are linked to containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machine. Stevanato Group S.p.A. was founded in 1949 and is based in Piombino Dese, Italy.
Most Popular Stories View All
STVN Latest News Stream
|Loading, please wait...|
STVN Latest Social Stream
View Full STVN Social Stream
Latest STVN News From Around the Web
Below are the latest news stories about Stevanato Group SpA that investors may wish to consider to help them evaluate STVN as an investment opportunity.
Italian vaccine vials maker Stevanato Group will use funds raised from its recent listing on the New York Stock Exchange to increase production capacity and for selected acquisitions, its executive chairman told Reuters on Thursday. According to its own estimates, it provides vials to about 90% of currently marketed COVID-19 vaccine programs. The medical packaging company raised $453.5 million in its July IPO and aims to build two new plants, which will focus on its high-margin products, including a drug containment solution called EZ-Fill.
PIOMBINO DESE, Italy, August 19, 2021--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter 2021 and established full-year 2021 guidance.
PIOMBINO DESE, Italy, August 11, 2021--Stevanato Group S.p.A. (NYSE: STVN) a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced that it will issue financial results for the second quarter of fiscal year 2021 on Thursday, August 19, 2021.
The group is diverse—a fintech, three biotechs, a real-estate investment manager, a bioscience company, and a pharmaceutical glassmaker.
(Reuters) -Italy's Stevanato Group S.p.A. made a tepid debut on the New York Stock Exchange as its shares slid, giving the world's second largest glass vial maker a valuation of $5 billion. Stevanato's shares fell more than 20% to open at $16.65 on Friday. "IPO is the best way to further finance the business...most of the proceeds of the IPO, we are going to invest in the new greenfield plants, one in Indiana, and one in China," said Franco Stevanato, executive chairman of the company's board.
STVN Price Returns